Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles.

[1]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[2]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[3]  Sidney C. Smith,et al.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.

[4]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[5]  S. Zyzanski,et al.  Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. , 1998, Circulation.

[6]  H. Krumholz,et al.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. , 1998, JAMA.

[7]  P. Shah,et al.  Lipid lowering versus revascularization: an idea whose time (for testing) has come. , 1997, Circulation.

[8]  G. Fonarow,et al.  Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. , 1997, Journal of the American College of Cardiology.

[9]  H. Krumholz,et al.  When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. , 1997, Circulation.

[10]  Philippe Amouyel,et al.  A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. , 1997 .

[11]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[12]  L. Keilson,et al.  Direct measurement of serum low-density lipoprotein cholesterol in patients with acute myocardial infarction on admission to the emergency room. , 1996, The American journal of cardiology.

[13]  T. Bowker,et al.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). , 1996, Heart.

[14]  V. Fuster,et al.  Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.

[15]  V. Fuster,et al.  AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. , 1995, Journal of the American College of Cardiology.

[16]  S. Yusuf,et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.

[17]  C. Dennis,et al.  A Case-Management System for Coronary Risk Factor Modification after Acute Myocardial Infarction , 1994, Annals of Internal Medicine.

[18]  C. Furberg,et al.  Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.

[19]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[20]  R. Anda,et al.  Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities. , 1993, JAMA.

[21]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[22]  B. Rifkind,et al.  The value of lowering cholesterol after myocardial infarction. , 1990, The New England journal of medicine.

[23]  S. Yusuf,et al.  Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. , 1990, Circulation.

[24]  C. Taylor,et al.  Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. , 1990, Annals of internal medicine.

[25]  J. Wittes,et al.  Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. , 1988, JAMA.

[26]  J. Gore,et al.  Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. , 1984, The American journal of cardiology.